Edmund Harrigan, M.D., has served as a director of Acadia since November 2015.
Dr. Harrigan served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015, where he led a 3,500-person team in 80 countries that was responsible for collecting, interpreting and reporting clinical safety data for more than 600 marketed products, and managed regulatory interactions with global health agencies. Dr. Harrigan’s previous executive leadership roles at Pfizer include serving as Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, and Vice President, Head of Neuroscience and Ophthalmology. Earlier in his career at Pfizer, Dr. Harrigan served as Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain.
Before entering the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years. He currently serves as a director of Incyte Corporation and PhaseBio Pharmaceuticals, Inc., and is a member of the Scientific Advisory Board of Karuna Therapeutics, Inc. Dr. Harrigan earned his B.A. in Chemistry from St. Anselm College, his M.D. from the University of Massachusetts at Worcester, and trained in neurology at Boston University.